CJC-1295 + Ipamorelin 5 mg + 5 mgPack de 10 flacons6 en stockÉconomisez 22 %
En vedettepeptideintermediate6 en stock

CJC-1295 + Ipamorelin 5 mg + 5 mg

Combinaison classique GHRH + mimétique de ghréline

CJC-1295 and Ipamorelin research stack, Australian-shipped. Lab-verified to ≥99% purity.

Dose
5mg + 5mg / flacon
Forme
Poudre lyophilisée
Pack
Pack de 10 flacons

Usage exclusivement réservé à la recherche. Ce composé est vendu strictement pour la recherche in vitro et à des fins de laboratoire, et n’est pas destiné à la consommation humaine ni à un usage thérapeutique. En achetant, vous confirmez être un chercheur qualifié et acceptez notre avertissement complet.

186 € EUR
Économisez 22 %
Pack de 10 flacons
Avant 238 € EUR
Vendu en pack de 10 flacons

Plus que 6 packs

🧪Vérifié en laboratoire
✓Testé par un tiers
⚡Livraison mondiale rapide
🔒Paiement par carte sécurisé
Aperçu

Flacon de recherche combinant l’analogue de GHRH CJC-1295 et le mimétique sélectif de ghréline Ipamorelin. La combinaison de sécrétagogues de GH à double mécanisme la plus étudiée.

CJC-1295 and Ipamorelin are a long-standing pair in growth-hormone secretagogue research. CJC-1295 is a 30-amino-acid analogue of growth-hormone-releasing hormone (GHRH); Ipamorelin is a selective ghrelin receptor agonist (a 'GHS' or growth-hormone secretagogue). The two compounds act on different receptors but converge on the somatotrophs of the anterior pituitary, where they amplify pulsatile growth-hormone release in pre-clinical models.

Quantum Labs supplies the pair as a pre-portioned research stack — two lyophilised vials shipped together, each HPLC-verified to ≥99% purity. Australian-shipped from local stock; supplied for laboratory research use only.

Mécanisme

CJC-1295 soutient la signalisation basale du récepteur GHRH tandis qu’Ipamorelin pilote des pulses sélectifs du récepteur de ghréline. La recherche suggère des schémas synergiques et naturalistes de libération de GH.

Rapport de laboratoire

Vérifié par HPLC selon une spécification de pureté ≥99 %. Analysé de manière indépendante par des laboratoires tiers accrédités.

CJC-1295: DAC vs no-DAC

CJC-1295 exists in two research forms: with Drug Affinity Complex (DAC) and without. The DAC variant binds albumin in plasma, extending the half-life from minutes to days. Research designs targeting acute pulsatile GH release typically use the no-DAC form (modified GRF 1-29); studies modelling sustained GH elevation use the DAC variant. Our supply is the no-DAC research-grade form unless otherwise specified.

FAQ chercheurs

CJC-1295 + Ipamorelin — questions fréquentes

What is the CJC-1295 + Ipamorelin stack?

It is a research pairing of two growth-hormone secretagogues: CJC-1295 (a GHRH analogue) and Ipamorelin (a selective ghrelin receptor agonist). The two compounds act on different receptors but converge on stimulating pulsatile growth-hormone release in pre-clinical models.

How does CJC-1295 differ from Ipamorelin?

CJC-1295 mimics growth-hormone-releasing hormone (GHRH), binding the GHRH receptor on pituitary somatotrophs. Ipamorelin mimics ghrelin, binding the growth-hormone secretagogue receptor (GHSR-1a). The two pathways are independent but synergistic — combining them produces a larger pulsatile GH response in research models than either compound alone.

Is CJC-1295 + Ipamorelin legal in Australia?

Both compounds are restricted for human therapeutic supply in Australia and remain available for research and laboratory use when supplied without therapeutic representation. Quantum Labs supplies the stack for research use only.

What does selective mean for Ipamorelin?

Ipamorelin is described as a selective ghrelin agonist because it activates the GH-release pathway with minimal effect on cortisol, prolactin, or aldosterone — distinguishing it from earlier-generation GHS molecules. This selectivity has made it a preferred research tool for isolating GH-specific effects.

What is the typical CJC-1295 + Ipamorelin research dosage?

Published research protocols have used wide dose ranges depending on the model and species. Human dosing is not established. Researchers should consult primary literature for protocol-specific guidance.

Are CJC-1295 and Ipamorelin used together?

Yes — combined-administration research is common precisely because the two compounds act on independent receptors and produce a synergistic GH-release response. The combination is a standard tool in growth-hormone secretagogue research.

Pour aller plus loin

Guides liés à CJC-1295 + Ipamorelin

Composés associés

Les chercheurs explorent aussi